Introduction
Sudden unpredictable cardiac arrest can cause myocardial dysfunction even when cardiopulmonary resuscitation is successful. Preconditioning can be an effective method of reducing cardiac dysfunction after global ischemia in organized clinical settings, such as cardiac surgery or cardiac catheterization, but it is not applicable for sudden unpredicted cardiac arrest [1] . The hemodynamic instability during the post-resuscitation period is generally treated with fl uid infusion, vasoactive agents such as norepinephrine, positive inotropic agents such as dobutamine, and inodilator agents such as phosphodiesterase (PDE) 3 inhibitors. However, these tools are not necessarily satisfying, and unfortunately, the strategies used, even those in the 2005 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care, seems not to be changed remarkably compared to the previously recommended strategies [2] . Thus, we were encouraged to seek a new strategy that could restore cardiac function after global ischemia.
Nitric oxide (NO) donors are promising candidates to relieve these situations, because NO is known to have inotropic effects under some conditions [3] . However, there is no obvious evidence that NO donors actually restore cardiac function, as a whole organ, after global ischemia. Instead, several studies report that NO donors exhibit biphasic contractile effects on the myocardium; i.e., low concentrations of NO donors reinforce cardiac contractility, whereas higher concentrations cancel such a benefi t [4] . One explanation for this phenomenon is that NO donors affect the intracellular concentrations of both cyclic guanosine monophosphate (cGMP) and cyclic adenosine monophosphate (cAMP) [5] .
The objective of this study was to investigate whether the NO donor, 3-(2-hydroxy-1-methyl-2-nitroso-hydrazino)-N-methyl-1-propanamine (NOC7), restored cardiac function following global ischemia in an isolated rat heart model, and whether intracellular messengers were involved in its effect. We also measured cAMP and cGMP concentrations, and we discuss their roles in the regulation of cardiac contractility, including their relationship to the concentration-effect of NOC7.
Materials and methods
The Institutional Animal Care Committee approved all experimental procedures and protocols used in the present study.
Isolated perfused rat heart and perfusion solution
Langendorff preparations of an isolated rat heart model and the perfusion solution used were basically as previously described, with minor modifi cations [6] . Briefl y, 36 male Sprague-Dawley rats, weighing 250 to 280 g, were used. The animals were anesthetized with pentobarbital (50 mg·kg ), was administered intravenously via the caudal vein. After the heart was isolated, the aorta was cannulated within 1 min. The heart was then perfused at a constant pressure of approximately 80 cmH 2 O. The perfusion solution was maintained at 37°C. A collapsed latex balloon was inserted into the left ventricular cavity via a left atrial incision, and we used an LB-2 latex balloon (Nihon Koden, Tokyo, Japan) for the measurement of pressure variables; the intra-balloon pressure was adjusted to [5] [6] [7] [8] [9] [10] 
Coronary fl ow was measured at a constant pressure and temperature by a transit-time, in-line ultrasound fl ow meter (MFV3200; Nihon Kohden).
The perfusion solution was a modifi ed KrebsHenseleit bicarbonate buffer (KHB) that was composed as follows (in mmol·l ): NaCl, 118; NaHCO 3 , 25; KCl, 4.7; CaCl 2 , 1.25; MgSO 4 , 1.2; KH 2 PO 4 , 1.2; and glucose, 11. The perfusion solution was gassed continuously with 95% oxygen and 5% carbon dioxide gas at 37°C to maintain P O 2 at more than 500 mmHg and pH approximately at 7.4.
Experimental protocol
After preparation, all hearts were subjected to an equilibration period of 20 min before baseline measurements. Those hearts in which LV systolic pressure was greater than or equal to 45 mmHg at the end of the equilibration period were the subject of the study. Subsequently, the hearts were randomly divided into six groups: 1. A sham control group, which was perfused with oxygenated KHB solution alone until the end of experiment, without global ischemia; the hearts in the other fi ve groups were subjected to 35 min of global ischemia by stopping perfusion with the oxygenated KHB solution, and then reperfused for 30 min [reperfusion period]. 2. An ischemic control group, which was perfused with KHB solution alone during the reperfusion period. 3-6. Four NOC7 groups, in which the hearts were perfused with KHB solution containing NOC7, at fi nal concentrations of 0.2, 2, 20, and 200 μM, during the reperfusion period (Fig. 1) . Myocardial function was assessed as the LVDP in the pre-and post-ischemic periods (5, 10, 20, and 30 min of reperfusion). Myocardium from the heart apex was collected at the end of the reperfusion period, frozen immediately in liquid nitrogen, and stored at −80°C until cyclic nucleotide analysis.
NOC7 (Dojindo Laboratories, Tokyo, Japan) was prepared in 10 mM NaOH, to make a 200-mM solution, and stored at 5°C. This solution was diluted to the fi nal concentrations of 0.2, 2, 20, or 200 μM just before use.
Cyclic nucleotide determination
Myocardial samples were homogenized and suspended in modifi ed Krebs-hydroxyethylpiperazine ethanesulfonic acid (HEPES) buffer (pH 7.4; 30°C). After the reactions were terminated with the addition of ice-cold trichloroacetic acid (TCA; fi nal concentration, 6%), the samples were centrifuged at 2000 g for 15 min at 4°C. The supernatants were collected, frozen, and stored at −80°C until cAMP and cGMP were determined, using an acetylation protocol for cAMP and cGMP (Biotrak enzyme immunoassay system [RPN225 and RPN226]; Amersham Biosciences, Piscataway, NJ, USA) according to the manufacturer's instructions. Levels of cyclic nucleotides in the samples were calculated as pmol cyclic nucleotide·mg −1 protein. The pellets were submitted for measurement of protein using a BCA Protein Assay Kit (Pierce, Rockford, IL, USA).
Statistical analysis
The values for results for each group were expressed as means ± SD. Differences within and between groups were determined by one-way analysis of variance and multiple comparisons, using the Tukey test with SPSS statistical analysis software 11.5 (SPSS, Chicago, IL, USA). A P value of less than 0.05 was regarded as statistically signifi cant.
Results

Hemodynamic function
Hemodynamic variables are shown in Figs. 2 and 3 and Table 1 . The baseline LVDP values were identical in all groups. Thirty-fi ve min of global ischemia reduced the LVDP to 13.0 ± 4.5% at 10 min of reperfusion, which represented an 85% reduction from the sham control value (P < 0.05). While 30-min reperfusion with KHB alone partially restored cardiac function, recovery was not complete; LVDP increased only slightly during reperfusion, resulting in a value of only 48.8 ± 6.1% of baseline (P < 0.05; Fig. 2 ). NOC7 improved myocardial performance, and signifi cantly restored LVDP, to 62.0 ± 6.0% and 67.3 ± 9.7% at 2 and 20 μM, respectively, with 20-min reperfusion from 36.8 ± 7.3% in the ischemic control group (P < 0.05). This effect of NOC7 was more prominent after 30 min of reperfusion, and the mean percent LVDP recovered to 111.9 ± 10.5% and 124.3 ± 12.5% of the After an equilibration period of 20 min, the sham control group did not undergo global ischemia, and instead, was perfused with modifi ed KrebsHenseleit bicarbonate buffer (KHB) alone until the end of the experiment. In the other groups, the hearts were subjected to 35 min of global ischemia, followed by 30 min of reperfusion.
During the reperfusion period, in the ischemic control group, the hearts were perfused with KHB alone. In the 3-(2-hydroxy-1-methyl-2-nitroso-hydrazino)-N-methyl-1-propanamine (NOC7) groups, the hearts were perfused with KHB solution containing different concentrations of NOC7 (0.2, 2, 20, or 200 μM as fi nal concentrations); n = 6 in each group . Data values are presented as means ± SD; n = 6 in each group. *P < 0.05 versus ischemic control. Data were analyzed using repeated-measure ANOVA followed by the Tukey test. Symbols, As in Fig. 2 * P < 0.05 vs ischemic control group; ** P < 0.05 vs baseline Results were reported as mean values ± (SD); n = 6 in each group. Differences within and between groups were determined by one-way analysis of variance and multiple comparisons using the Tukey test baseline at 2 and 20 μM, respectively. These values were obviously greater than the 48.8 ± 6.1% in the ischemic control, and rather close to the sham control level of 88.4 ± 3.1% (P < 0.05; Figs. 2 and 3) . The highest concentration of NOC7, however, reversed this positive inotropic effect, and LVDP deteriorated again to 55.3 ± 6.0% of the baseline, similar to the value of 51.0 ± 11.5% with 0.2 μM NOC7 or the 48.8 ± 6.1% in the ischemic control. During ischemia, LVEDP increased in all groups, indicating the development of myocardial contracture. With the onset of reperfusion, there was a further increase in LVEDP to values between 69 and 85 mmHg (reperfusion contracture). NOC7 at 2 and 20 μM significantly recovered LVEDP, to 41.6 ± 8.8 and 45.9 ± 4.7 mmHg, respectively, in comparison to the ischemic control value of 65.6 ± 9.6 mmHg at 30 min of reperfusion (P < 0.05; Table 1) .
In all groups, the recovery of dP/dt max as a variable of myocardial contractility paralleled the recovery of LVDP (Fig. 3) . The mean stabilized dP/dt max at baseline was 3393 ± 131 mmHg·s , respectively; P < 0.05). As a variable of diastolic function, dP/dt min changed in a similar manner and was improved by NOC7 at 2 and 20 μM (Table 1) . Coronary fl ow remain unchanged.
Cyclic nucleotide concentrations
The average myocardial cAMP level, in the sham control group was 2.34 ± 0.21 pmol·mg −1 protein, and this was demonstrated a biphasic effect of NO donors in papillary muscle [4] . Our present report is the fi rst one to reveal a similar effect of an NO donor in isolated whole heart; i.e., a biphasic effect on contractile force after global ischemia. In our study, NOC7 at concentrations of 2, 20, and 200 μM increased myocardial cAMP levels (Fig. 4) . In contrast with the changes in myocardial cAMP, NOC7 at 2 and 20 μM changed myocardial cGMP levels slightly, with the changes did not reaching statistical signifi cance (Fig. 5) . NO, donors produce NO, which activates a guanylyl cyclase to derive cGMP. Even a moderate increase in cGMP is reported to inhibit myocardial PDE3, and cAMP degradation is then suppressed, which results in an elevated intracellular cAMP level in the myocardium [4] . Furthermore, NO was reported to activate adenylyl cyclase (AC) without the cGMP mediated pathway [7] . This cGMP-independent activation of AC may have induced the increased cAMP levels in the myocardium found in our study. Elevated cAMP acts through a protein kinase A (PKA) to positively affect myocardial function. The cGMP produced in the myocardium may also act directly on the myocardium, through protein kinase G (PKG) activation, to negatively affect myocardial function [8] . In our study, with NOC7 at concentrations of 2 and 20 μM, however, the negative inotropic effect exerted by cGMP may have been masked by the positive effect of the elevated cAMP levels [9, 10] .
On the other hand, NOC7 at 200 μM, the highest concentration used in the present study, resulted in a signifi cant increase in cGMP (Fig. 5) . In spite of the Fig. 4 . The effects of NOC7 on intracellular cyclic adenosine monophosphate (AMP). *P < 0.05 versus ischemic control. Data were analyzed using repeated-measure ANOVA followed by the Tukey test protein, respectively (P < 0.05). The cGMP level in the sham control group was 2.36 ± 0.25 pmol·mg −1 protein, whereas that in the ischemic control group was 1.49 ± 0.61 pmol·mg −1 protein (Fig.   5 ). Following treatment with NOC7 at 2 and 20 μM, the cGMP level changed slightly, but the change did not reach statistical signifi cance. NOC7 at 200 μM significantly increased the cGMP level to 3.92 ± 0.66 pmol· mg −1 protein (P < 0.05 versus ischemic control).
Discussion
In the present study, we used the Langendorff-perfused isolated rat heart model. This experimental setting excludes the infl uence of systemic hemodynamics such as preload and afterload, as well as excluding most humoral effects and sympathetic/parasympathetic control from the central nervous systems, which can be affected by NO donors. We regard this method as the best choice among of heart-model to examine the direct myocardial effects of NOC7. Our results demonstrated that NOC7 at concentrations of 2 and 20 μM restored cardiac function after ischemia, as assessed by LVDP, dP/dt max , and dP/dt min . However, NOC7 at 200 μM, the highest concentration in our present study, lost this positive inotropic effect. This fi nding corresponds with a previous report that elevated cAMP levels induced by NOC7 at 200 μM, the positive inotropic effect of NOC7 was reversed, and cardiac function was seen to be similar to that in the ischemic control group. In such, an instances, it has been shown that exogenous NO donor increased the intracellular cGMP level and that under this condition, activated PKG phosphorylated troponin I, which led to myofi lament relaxation [11] . In our study, this negative effect on myocardial function of increased cGMP seems to have been dominant, and it overcame the positive effects of cAMP. Of note, NO can reversibly reduce myocardial contractility through a cGMP-independent pathway, i.e., by binding to the oxygen-binding site of cytochrome oxidase in competition with oxygen in the presence of hypoxia. Furthermore, NO or its derivative N 2 O 3 or S-nitrosothiols, may inactivate complex I, one of the components of the mitochondrial respiratory chain, by S-nitrosation, and thus inhibit ATP production and susceptibility to cell death [12] [13] [14] . These direct negative effects of NO, which are independent of the cGMP-PKG pathway, may be considered to have induced the cardiac dysfunction seen at 200 μM of NOC7 in the present study.
As for different possibilities to explain the observed phenomenon of the reversal of cardiac function by NOC7 at 200 μm, free radical production and calcium overload are considered to be implicated in the development of myocardial ischemia and reperfusion injury [15] [16] [17] . Furthermore, elevated NO may lead to the concomitant production of ONOO − , which contributes to cardiac dysfunction [18] . Although we did not measure these factors, they may also have contributed to the reversal of cardiac function induced by NOC7 at 200 μM. Further study is necessary to elucidate these mechanisms. Several authors report that NO donors increase coronary fl ow and improve cardiac function. For instance, L-arginine, at 25-1000-fold higher potency for NO production than that in our study, increased post-ischemic coronary fl ow [19] [20] [21] . In the present study, however, coronary fl ows were maintained at constant levels regardless of the NOC7 concentration ( Table 1 ). The contractile recovery in our model is not likely to have been due to recovered oxygen supply as a result of increased coronary fl ow.
In the clinical situation, organic NO donors (sodium nitroprusside, nitroglycerine) or authentic NO are currently being used as vasodilators for critical/intensive care. Following our present results, the clinical application of NO donors as inotropic agents, in patients with cardiac dysfunction during post-resuscitation period can be considered. Although further investigations will be necessary before this practical use of NO donors can be implemented, we can expect a considerable benefi t when they are employed at appropriate concentrations.
Conclusion
In summary, the NO donor, NOC7, exerted biphasic effect on the contractile force of the isolated rat heart after global ischemia. The balance between intracellular cAMP and cGMP levels seemed to be involved in this mechanism of NOC7. The use of a specifi c concentration range of NO donors may be one option for the restoration of cardiac function.
